Kalvista Pharmaceuticals Company Insiders
| KALV Stock | USD 11.65 0.23 1.94% |
Slightly above 81 percent of all Kalvista Pharmaceuticals' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Kalvista Pharmaceuticals suggests that a fairly large number of insiders are very bullish. Kalvista Pharmaceuticals employs about 118 people. The company is managed by 25 executives with a total tenure of roughly 119 years, averaging almost 4.0 years of service per executive, having 4.72 employees per reported executive.
| Thomas Crockett CEO CEO, Director |
| Richard Aldrich Chairman Chairman of the Board |
Kalvista Pharmaceuticals' Insider Buying Vs Selling
81
Selling | Buying |
Latest Trades
| 2024-02-20 | Benjamin L Palleiko | Disposed 22802 @ 14.11 | View | ||
| 2024-02-08 | Venrock Healthcare Capital Par | Acquired 29747 @ 14.7 | View | ||
| 2024-02-06 | Venrock Healthcare Capital Par | Acquired 4474 @ 14.74 | View | ||
| 2024-01-29 | Venrock Healthcare Capital Par | Acquired 80600 @ 14.22 | View | ||
| 2024-01-26 | Venrock Healthcare Capital Par | Acquired 4174 @ 12.98 | View | ||
| 2024-01-24 | Venrock Healthcare Capital Par | Acquired 20686 @ 12.44 | View | ||
| 2024-01-22 | Venrock Healthcare Capital Par | Acquired 67546 @ 12.55 | View | ||
| 2024-01-18 | Venrock Healthcare Capital Par | Acquired 39680 @ 12.51 | View | ||
| 2024-01-16 | Venrock Healthcare Capital Par | Acquired 19599 @ 12.73 | View | ||
| 2024-01-11 | Edward P Feener | Disposed 22679 @ 13.03 | View | ||
| 2024-01-10 | Venrock Healthcare Capital Par | Acquired 47700 @ 12.67 | View | ||
| 2024-01-08 | Venrock Healthcare Capital Par | Acquired 69184 @ 12.44 | View | ||
| 2024-01-03 | Venrock Healthcare Capital Par | Acquired 17605 @ 12.2 | View | ||
| 2023-12-29 | Venrock Healthcare Capital Par | Acquired 6013 @ 12.49 | View | ||
| 2023-12-27 | Venrock Healthcare Capital Par | Acquired 41514 @ 11.97 | View | ||
| 2023-09-11 | Albert Cha | Disposed 18000 @ 10.5 | View |
Monitoring Kalvista Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Kalvista |
Kalvista Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Kalvista Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Kalvista will maintain a workforce of slightly above 120 employees by May 2024.Kalvista Pharmaceuticals' latest congressional trading
Congressional trading in companies like Kalvista Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Kalvista Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
| 2022-12-12 | Representative Chris Jacobs | Acquired Under $15K | Verify |
Kalvista Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.425) % which means that it has lost $0.425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7933) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.17 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (1.03). At this time, Kalvista Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 13.1 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 40.9 M in 2024.Common Stock Shares Outstanding is likely to climb to about 33.7 M in 2024, whereas Net Loss is likely to drop (26.1 M) in 2024.
Kalvista Pharmaceuticals Workforce Comparison
Kalvista Pharmaceuticals is currently regarded as number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 32,944. Kalvista Pharmaceuticals adds roughly 118 in number of employees claiming only tiny portion of equities under Health Care industry.
Kalvista Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kalvista Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kalvista Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kalvista Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 1.0 | 36 | 36 | 2,414,704 | 493,227 |
| 2023-12-01 | 0.3636 | 8 | 22 | 624,321 | 191,175 |
| 2023-09-01 | 0.5217 | 12 | 23 | 173,294 | 189,375 |
| 2023-06-01 | 0.4 | 6 | 15 | 76,971 | 53,805 |
| 2023-03-01 | 0.5789 | 11 | 19 | 317,244 | 72,818 |
| 2022-12-01 | 0.9 | 9 | 10 | 54,191 | 19,089 |
| 2022-09-01 | 0.25 | 3 | 12 | 9,996 | 26,931 |
| 2022-03-01 | 0.6667 | 2 | 3 | 57,657 | 67,657 |
| 2021-09-01 | 1.25 | 5 | 4 | 50,000 | 21,000 |
| 2021-06-01 | 0.4444 | 16 | 36 | 676,558 | 400,896 |
| 2021-03-01 | 0.7895 | 15 | 19 | 391,142 | 125,284 |
| 2020-12-01 | 0.8095 | 17 | 21 | 587,044 | 90,316 |
| 2019-12-01 | 0.5833 | 7 | 12 | 28,355 | 24,710 |
| 2019-09-01 | 2.2 | 11 | 5 | 135,002 | 28,010 |
| 2019-06-01 | 0.4074 | 11 | 27 | 201,828 | 221,938 |
| 2019-03-01 | 0.0851 | 4 | 47 | 21,355 | 1,373,239 |
| 2018-12-01 | 0.4 | 4 | 10 | 28,000 | 60,440 |
| 2018-09-01 | 9.0 | 9 | 1 | 1,491,148 | 2,500 |
| 2017-12-01 | 0.3333 | 3 | 9 | 2,265,065 | 2,725,283 |
| 2017-09-01 | 1.0 | 7 | 7 | 42,000 | 353,291 |
| 2016-12-01 | 1.8 | 18 | 10 | 7,482,195 | 79,801 |
| 2015-12-01 | 0.5 | 1 | 2 | 10,000 | 20,000 |
| 2015-06-01 | 1.6552 | 48 | 29 | 30,130,798 | 10,321,258 |
Kalvista Pharmaceuticals Notable Stakeholders
A Kalvista Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kalvista Pharmaceuticals often face trade-offs trying to please all of them. Kalvista Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kalvista Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Thomas Crockett | CEO, Director | Profile | |
| Richard Aldrich | Chairman of the Board | Profile | |
| Andreas Maetzel | Senior Vice President Medical | Profile | |
| Benjamin Palleiko | Chief President | Profile | |
| Arnold Oronsky | Director | Profile | |
| Brian Pereira | Director | Profile | |
| Edward Unkart | Independent Director | Profile | |
| Daniel Soland | Director | Profile | |
| Stephen Donnelly | Director Secretary | Profile | |
| Martin Edwards | Director | Profile | |
| Albert Cha | Independent Director | Profile | |
| Joshua Resnick | Director | Profile | |
| Rajeev Shah | Director | Profile | |
| Jarrod Aldom | Vice Communications | Profile | |
| Ryan Baker | Head Relations | Profile | |
| John McKune | VP Fin | Profile | |
| Christopher Yea | Chief Development Officer | Profile | |
| Rachel Morten | Senior QA | Profile | |
| Nicole Sweeny | Chief Officer | Profile | |
| Thomas MBA | CEO Director | Profile | |
| Michael PharmD | Senior Development | Profile | |
| David Burke | IR Contact Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Edward Feener | Chief Scientific Officer | Profile | |
| Brian JD | General Counsel | Profile |
About Kalvista Pharmaceuticals Management Performance
The success or failure of an entity such as Kalvista Pharmaceuticals often depends on how effective the management is. Kalvista Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kalvista management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kalvista management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.09) | (1.03) | |
| Return On Capital Employed | 18.02 | 18.92 | |
| Return On Assets | (1.09) | (1.03) | |
| Return On Equity | 0.16 | 0.17 |
The data published in Kalvista Pharmaceuticals' official financial statements usually reflect Kalvista Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kalvista Pharmaceuticals. For example, before you start analyzing numbers published by Kalvista accountants, it's critical to develop an understanding of what Kalvista Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Kalvista Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kalvista Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kalvista Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kalvista Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Kalvista Pharmaceuticals' management manipulating its earnings.
Kalvista Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Kalvista Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kalvista Pharmaceuticals within its industry.Kalvista Pharmaceuticals Manpower Efficiency
Return on Kalvista Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 787.3K | |
| Net Loss Per Executive | 3.7M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 6.3M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Kalvista Stock analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Kalvista Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kalvista Pharmaceuticals. If investors know Kalvista will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kalvista Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.12) | Revenue Per Share 0.214 | Quarterly Revenue Growth 0.307 | Return On Assets (0.42) | Return On Equity (0.79) |
The market value of Kalvista Pharmaceuticals is measured differently than its book value, which is the value of Kalvista that is recorded on the company's balance sheet. Investors also form their own opinion of Kalvista Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kalvista Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kalvista Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kalvista Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kalvista Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kalvista Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kalvista Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.